A new study investigated how effective a two-dose SARS-CoV-2 vaccine regimen is for patients receiving Rituximab. Researchers measured the humoral and cellular immune responses, which correlate to antibody and T-cell production, respectively.
Read More »A new study investigated vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, in SLE patients. This is one of the first studies on vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, especially in an autoimmune disease patient cohort.
Read More »A recent study evaluated the safety and efficacy of the Moderna, Pfizer, and Johnson & Johnson COVID-19 vaccines in dermatomyositis (DM) patients compared to non-DM patients at 1, 30, and 60 days post-vaccination. At 60 days post-vaccination, the DM group was observed to be at greater risk for adverse events of special interest compared to controls, albeit very small (absolute risk was .6%). No differences were observed for breakthrough infection or all-cause hospitalization at 60 days post-vaccination.
Read More »Read synopses of how each vaccine fares against the Omicron variant according to the latest data:
Read More »